



Andrew Rezvani, M.D.

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic F

MC 6560

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 725-8950

- **Blood and Marrow Transplant Program**

300 Pasteur Dr Rm H0101

MC 5623

Stanford, CA 94305

Tel (650) 723-0822 **Fax** (650) 498-6919

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Janice Smith - Administrative Associate

Email janices1@stanford.edu

Tel (650) 724-4155

Bio

BIO

Dr. Rezvani is an Associate Professor of Medicine in the Division of Blood & Marrow Transplantation and Cell Therapy. He serves as the medical director of the inpatient BMT/cell therapy units at Stanford University and as Associate Clinical Chief of the Division. As a clinician, he cares for people undergoing allogeneic and autologous hematopoietic cell transplantation and other forms of cellular therapy. His research interests include optimizing the use of alternative donors for people who lack traditional fully-matched donors; the prevention and treatment of graft-vs.-host disease; the role of the microbiome in hematopoietic cell transplantation; and quality-of-care and systems improvement. He also teaches and serves as a research mentor for trainees in the Division of Blood & Marrow Transplant at Stanford.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Medical Oncology
- CAR T Cell Therapy

ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Associate Clinical Chief, Stanford University, Division of Blood & Marrow Transplantation, (2020- present)
- Inpatient Medical Director, Blood & Marrow Transplant Unit, Stanford University, (2017- present)

- Quality & Safety Director, Division of Blood & Marrow Transplantation, (2021- present)
- Cord Blood and Unrelated-Donor Director, Stanford University, Division of Blood & Marrow Transplantation, (2018- present)

HONORS AND AWARDS

- Member, Alpha Omega Alpha medical honor society (2001)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Cord Blood Advisory Group, National Marrow Donor Program (2019 - present)
- Member, Protocol Development Committee, Protocol 1703, Blood & Marrow Transplant Clinical Trials Network (BMT-CTN) (2017 - present)
- Member, Conflict of Interest Committee, Blood & Marrow Transplant Clinical Trials Network (BMT-CTN) (2018 - present)
- Member, Toxicity and Supportive Care Committee, Blood & Marrow Transplant Clinical Trials Network (BMT-CTN) (2015 - 2018)
- Editorial consultant, American College of Physicians PIER (2008 - 2016)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2021)
- Fellowship, Fred Hutchinson Cancer Research Center/University of Washington , Medical Oncology (2008)
- Residency, Duke University Medical Center , Internal Medicine (2004)
- M.D., Temple University , Medicine (2001)
- B.A., Stanford University , Slavic Languages and Literature (1997)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical research in allogeneic hematopoietic cell transplantation

CLINICAL TRIALS

- Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies, Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Recruiting
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies, Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Recruiting
- MAGE A10####T for Advanced NSCLC, Recruiting
- Safety Study of Cord Blood Units for Stem Cell Transplants, Recruiting
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs), Not Recruiting
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Not Recruiting
- Aromatherapy for HSCT Distress, Not Recruiting
- Axicabtagene Ciloleucel Expanded Access Study, Not Recruiting
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Not Recruiting
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation, Not Recruiting

- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Efficacy of Axicabtagene Ciloleucef Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies, Not Recruiting
- Expanded Access Protocol for Tabelecleucef for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting
- Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant, Not Recruiting
- Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant, Not Recruiting
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors, Not Recruiting
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS, Not Recruiting
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease, Not Recruiting
- TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801), Not Recruiting

Publications

PUBLICATIONS

- **Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.** *British journal of haematology*
Savani, M., Ahn, K. W., Chen, Y., Ahmed, S., Cashen, A. F., Shadman, M., Modi, D., Khimani, F., Cutler, C. S., Zain, J., Brammer, J. E., Rezvani, A. R., Fenske, et al
1800
- **Rare transmission of commensal and pathogenic bacteria in the gut microbiome of hospitalized adults.** *Nature communications*
Siranosian, B. A., Brooks, E. F., Andermann, T., Rezvani, A. R., Banaei, N., Tang, H., Bhatt, A. S.
1800; 13 (1): 586
- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
1800
- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
2021; 5 (21): 4465-4475
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021

- **A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial.** *Transplantation and cellular therapy*
Andermann, T. M., Fouladi, F., Tamburini, F. B., Sahaf, B., Tkachenko, E., Greene, C., Buckley, M. T., Brooks, E. F., Hedlin, H., Arai, S., Mackall, C. L., Miklos, D., Negrin, et al
2021
- **Engraftment of double cord blood transplantation after non-myeloablative conditioning with escalated total body irradiation dosing to facilitate engraftment in immunocompetent patients.** *Transplantation and cellular therapy*
Brunstein, C. G., DeFor, T. E., Fuchs, E. J., Karanes, C., McGuirk, J. P., Rezvani, A. R., Eapen, M., O'Donnell, P. V., Weisdorf, D. J., Blood and Marrow Transplant Clinical Trials Network.,
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.** *Blood*
Horwitz, M. E., Stiff, P. J., Cutler, C. S., Brunstein, C. G., Hanna, R., Maziarz, R. T., Rezvani, A. R., Karras, N. A., McGuirk, J. P., Valcarcel, D., Schiller, G. J., Lindemans, C. A., Hwang, et al
2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al
SPRINGERNATURE.2021: 181
- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.** *JAMA oncology*
Scordo, M., Wang, T. P., Ahn, K. W., Chen, Y., Ahmed, S., Awan, F. T., Beitinjaneh, A., Chen, A., Chow, V. A., Dholaria, B., Epperla, N., Farooq, U., Ghosh, et al
2021
- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia.** *Transplantation and cellular therapy*
Metheny, L., Politikos, I., Ballen, K. K., Rezvani, A. R., Milano, F., Barker, J. N., Brunstein, C. G., American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group
2021; 27 (4): 286-91
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021
- **Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.** *Blood*
Fuchs, E. J., O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., Devine, S., Horowitz, M. M., Horowitz, M. E., Karanes, C., Leifer, E., Magenau, J. M., McGuirk, et al
2021; 137 (3): 420-428
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al

2021; 5 (1): 143-155

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143-55
- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
2021
- **Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes.** *Transplantation and cellular therapy*
O'Donnell, P. V., Brunstein, C. G., Fuchs, E. J., Zhang, M. J., Allbee-Johnson, M., Antin, J. H., Leifer, E. S., Elmariah, H., Grunwald, M. R., Hashmi, H., Horowitz, M. M., Magenau, J. M., Majhail, et al
2021
- **Results of Bmt Ctn Protocol 1101 a Multicenter Phase Iii Randomized Trial of Transplantation of Double Umbilical Cord Blood vs. Hla-haploidentical-related Bone Marrow**
Brunstein, C., O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., Devine, S., DiFronzo, N., Horowitz, M. M., Horwitz, M. E., Karanes, C., Leifer, E., Magenau, et al
SPRINGERNATURE.2020: 16-17
- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
2020
- **Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101).** *Blood*
Fuchs, E. J., O'Donnell, P. V., Eapen, M., Logan, B. R., Antin, J. H., Dawson, P., Devine, S. M., Horowitz, M. M., Horwitz, M. E., Karanes, C., Leifer, E., Magenau, J. M., McGuirk, et al
2020
- **Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Granot, N., Rezvani, A. R., Pender, B. S., Storer, B. E., Sandmaier, B. M., Storb, R., Maloney, D. G.
2020
- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.** *Blood advances*
Kahn, J. M., Brazauskas, R., Tecca, H. R., Bo-Subait, S., Buchbinder, D., Battiwala, M., Flowers, M. E., Savani, B. N., Phelan, R., Broglie, L., Abraham, A. A., Keating, A. K., Daly, et al
2020; 4 (9): 2084-94
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
ELSEVIER SCIENCE INC.2020: S106
- **Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients**
Muffly, L., Ramirez, Y., Burnash, S., Bisetti, E., Rezvani, A., Sundaram, V.
ELSEVIER SCIENCE INC.2020: S199
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*

- Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Tamaresis, J. S., Ehlinger, et al
2020
 - **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
2020; 4 (18): 4474-82
 - **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
 - **No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial**
Milano, F., Rezvani, A. R., Kurtzberg, J., Karanes, C., Gutman, J. A., Duncan, C., Keyzner, A., Hanna, R., Marmon, T., Dahlberg, A., Delaney, C.
AMER SOC HEMATOLOGY.2019
 - **Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents**
Sica, R., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., Meyer, E. H., Miklos, D. B., Muffly, L. S., Rezvani, A. R., Shizuru, J. A., Weng, W., Negrin, et al
AMER SOC HEMATOLOGY.2019
 - **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
2019; 4 (10)
 - **Daily Dosing of Busulfan in Allogeneic Hematopoietic Cell Transplantation Reduces Costs with Equivalent or Superior Outcomes**
Singhal, S., Kim, T. Y., Tierney, D., Rezvani, A.
ELSEVIER SCIENCE INC.2019
 - **Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients**
Gandhi, A., Rezvani, A., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., Arai, S., Muffly, L., Meyer, E. H., Negrin, R. S., Weng, W.
ELSEVIER SCIENCE INC.2019
 - **Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.** *Journal of hematology & oncology*
Epperla, N., Ahn, K. W., Litovich, C., Ahmed, S., Battiwalla, M., Cohen, J. B., Dahi, P., Farhadfar, N., Farooq, U., Freytes, C. O., Ghosh, N., Haverkos, B., Herrera, et al
2019; 12 (1): 6
 - **Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Aronson, J. R., Rezvani, A. R., Subramanian, A. n.
2019
 - **Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Singhal, S. n., Kim, T. n., Jenkins, P. n., Bassett, B. n., Tierney, D. K., Rezvani, A. R.
2019
 - **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al

2019; 3 (16): 2454–64

- **Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.** *Blood advances*
Multani, A. n., Allard, L. S., Wangjam, T. n., Sica, R. A., Epstein, D. J., Rezvani, A. R., Ho, D. Y.
2019; 3 (22): 3602–12
- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2018
- **Elevated Axicabtagene Ciloleuce (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
AMER SOC HEMATOLOGY.2018
- **Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Casulo, C., Friedberg, J. W., Ahn, K. W., Flowers, C., DiGilio, A., Smith, S. M., Ahmed, S., Inwards, D., Aljurf, M., Chen, A., Choe, H., Cohen, J., Copelan, et al
2018; 24 (6): 1163–71
- **Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis** *BLOOD ADVANCES*
Shah, N. N., Ahn, K., Litovich, C., Fenske, T. S., Ahmed, S., Battiwala, M., Bejanyan, N., Dahi, P. B., Bolanos-Meade, J., Chen, A. I., Ciurea, S. O., Bachanova, V., DeFilipp, et al
2018; 2 (8): 933–40
- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
2018; 2 (6): 681–90
- **Viral Isolates in the Cerebrospinal Fluid of Hematopoietic Stem Cell Transplant Recipients, 2007-2015**
Andermann, T., Asiimwe, E., Buckley, M., Tkachenko, E., Greene, C., Rezvani, A., Bhatt, A. S.
ELSEVIER SCIENCE INC.2018: S378–S379
- **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**
Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffly, et al
ELSEVIER SCIENCE INC.2018: S145
- **Acute Graft-versus-Host Disease** *NEW ENGLAND JOURNAL OF MEDICINE*
Rezvani, A. R.
2018; 378 (6): 585–86
- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
2017; 23 (10): 1744–48
- **Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States** *BLOOD*
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., Battiwala, M., Beitinjaneh, A., Cahn, et al
2017; 130 (9): 1156–64
- **Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.** *Cancer*
Weisdorf, D. J., Millard, H. R., Horowitz, M. M., Hyare, P. S., Champlin, R., Ho, V., Mielcarek, M., Rezvani, A., Stockerl-Goldstein, K., Khoury, H. J., de Lima, M., Saber, W., Sandmaier, et al
2017
- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al

2017; 1 (17): 1347-57

- **Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.** *Journal of hematology & oncology*
Epperla, N. n., Ahn, K. W., Ahmed, S. n., Jagasia, M. n., DiGilio, A. n., Devine, S. M., Jaglowski, S. n., Kennedy, V. n., Rezvani, A. R., Smith, S. M., Sureda, A. n., Fenske, T. S., Kharfan-Dabaja, et al
2017; 10 (1): 117
- **Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors**
Spinner, M. A., Vina, M., Elder, L., Arai, S., Johnston, L., Meyer, E., Miklos, D., Muffly, L., Negrin, R. S., Shizuru, J., Weng, W., Laport, G. G., Strober, et al
AMER SOC HEMATOLOGY.2016
- **Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation**
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
AMER SOC HEMATOLOGY.2016
- **Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.** *Blood*
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., Brown, J. R., Dyer, M. J., Mato, A. R., Keating, M. J., Jaglowski, S., Clow, F., Rezvani, et al
2016
- **A new standard for HIV-associated lymphoma.** *Blood*
Rezvani, A. R.
2016; 128 (8): 1026-1027
- **Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myceloablative allogeneic stem cell transplantation.**
Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L. S., Negrin, R., Rezvani, A. R., Shizuru, J., Weng, W., Johnston, L. J.
AMER SOC CLINICAL ONCOLOGY.2016
- **Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.**
Neppalli, A., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W., Negrin, R., Meyer, E., Laport, G., Lowsky, R., Arai, S., Miklos, D., Rezvani, A. R.
AMER SOC CLINICAL ONCOLOGY.2016
- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al
ELSEVIER SCIENCE INC.2016: S204-S205
- **Immune Characterization of Ibrutinib Therapy Following Allohet That Provides GVL Benefit without Gvhd**
Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., Lowsky, R., Negrin, R., Miklos, D. B.
ELSEVIER SCIENCE INC.2016: S412
- **Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors** *BLOOD*
Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., Ahn, K. W., DiGilio, A., Beitinjane, A., Chhabra, S., Fenske, T. S., Freytes, C., Gale, R. P., Ganguly, S., Hertzberg, M., Klyuchnikov, et al
2016; 127 (7): 938-947
- **Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation** *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*
Andermann, T. M., Rezvani, A., Bhatt, A. S.
2016; 11 (1): 19-28
- **Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation.** *Current hematologic malignancy reports*
Andermann, T. M., Rezvani, A., Bhatt, A. S.
2016
- **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al
AMER SOC HEMATOLOGY.2015

- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis**
Logan, A. C., Herrera, A. F., Ryan, C. E., Rezvani, A. R., Kong, K. A., Faham, M., Alatrash, G., Molldrem, J. J., Sargent, R. L., Alyea, E. P., Ho, V. T., Brown, J. R., Ritz, et al
AMER SOC HEMATOLOGY.2015
- **Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.** *Cancer*
Vaughn, J. E., Sorror, M. L., Storer, B. E., Chauncey, T. R., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., Hari, P., Laport, G. G., Franke, G. N., Agura, E. D., Langston, A. A., Rezvani, et al
2015; 121 (20): 3709-3716
- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al
2015; 50 (10): 1286-1292
- **Long-term outcomes of patients with persistent indolent b cell malignancies undergoing nonmyeloablative allogeneic transplantation.** *Biology of blood and marrow transplantation*
Cassaday, R. D., Storer, B. E., Sorror, M. L., Sandmaier, B. M., Guthrie, K. A., Maloney, D. G., Rajendran, J. G., Pagel, J. M., Flowers, M. E., Green, D. J., Rezvani, A. R., Storb, R. F., Press, et al
2015; 21 (2): 281-287
- **Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning**
Vaughn, J., Sorror, M. L., Chauncey, T., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., Hari, P. N., Laport, G. G., Franke, G., Agura, E., Langston, A., Rezvani, A., Stor, et al
ELSEVIER SCIENCE INC.2015: S88–S89
- **Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation**
Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., Otani, J., Kong, K. A., Klinger, M., Faham, M., Coutre, S., Miklos, D. B.
ELSEVIER SCIENCE INC.2015: S307–S308
- **Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.** *Biology of blood and marrow transplantation*
Rezvani, A. R., Storer, B. E., Guthrie, K. A., Schoch, H. G., Maloney, D. G., Sandmaier, B. M., Storb, R.
2015; 21 (1): 105-112
- **Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation**
Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., Otani, J., Kong, K. A., Klinger, M., Faham, M., Coutre, S., Miklos, D. B.
AMER SOC HEMATOLOGY.2014
- **Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes** *CURRENT OPINION IN HEMATOLOGY*
Rezvani, A. R., Sandmaier, B. M.
2013; 20 (6): 509-514
- **Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.** *Transplantation*
Sato, M., Storb, R., Loretz, C., Stone, D., Mielcarek, M., Sale, G. E., Rezvani, A. R., Graves, S. S.
2013; 96 (1): 34-41
- **Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, A. R., McCune, J. S., Storer, B. E., Batchelder, A., Kida, A., Deeg, H. J., McDonald, G. B.
2013; 19 (7): 1033-1039

- **Prevention of graft-vs.-host disease** *EXPERT OPINION ON PHARMACOTHERAPY*
Rezvani, A. R., Storb, R. F.
2012; 13 (12): 1737-1750
- **The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation** *BLOOD*
Scott, B. L., Gooley, T. A., Sorror, M. L., Rezvani, A. R., Linenberger, M. L., Grim, J., Sandmaier, B. M., Myerson, D., Chauncey, T. R., Storb, R., Buxhofer-Ausch, V., Radich, J. P., Appelbaum, et al
2012; 119 (11): 2657-2664
- **Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Yeh, R. F., Pawlikowski, M. A., Blough, D. K., McDonald, G. B., O'Donnell, P. V., Rezvani, A., Deeg, H. J., McCune, J. S.
2012; 18 (2): 265-272
- **Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, A. R., Storer, B. E., Storb, R. F., Mielcarek, M., Maloney, D. G., Sandmaier, B. M., Martin, P. J., McDonald, G. B.
2011; 17 (11): 1594-1601
- **Rituximab resistance** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Rezvani, A. R., Maloney, D. G.
2011; 24 (2): 203-216
- **Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors.**
Sorror, M. L., Storer, B., Sandmaier, B. M., Franke, G. N., Laport, G. G., Chauncey, T., Agura, E., Maris, M. T., Wade, J., Pulsipher, M. A., Maziarz, R. T., Sahebi, F., McSweeney, et al
AMER SOC HEMATOLOGY.2010: 553
- **Allogeneic hematopoietic cell transplantation: the state of the art** *EXPERT REVIEW OF HEMATOLOGY*
Gyurkocza, B., Rezvani, A., Storb, R. F.
2010; 3 (3): 285-299
- **Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Flowers, M. E., Storer, B., Carpenter, P., Rezvani, A. R., Vigorito, A. C., Campregher, P. V., Moravec, C., Kiem, H., Fero, M., Georges, G., Warren, E., Lee, S., Sanders, et al
2008; 14 (12): 1380-1384
- **Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience** *7th International Meeting on AAA Proteins*
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., Agura, E., Chauncey, T., Maziarz, R. T., Maris, M., Shizuru, J., Bruno, B., Bredeson, et al
WILEY-BLACKWELL PUBLISHING, INC.2008: 395-403
- **Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation** *Center of Excellence Meeting*
Rezvani, A. R., Storb, R. F.
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD.2008: 172-79
- **Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Rezvani, A. R., Storb, R.
2008; 8 (2): 161-179
- **Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma** *48th Annual Meeting of the American-Society-of-Hematology*
Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., Wade, J. C., Chauncey, T., Forman, S. J., Lange, T., Shizuru, J., Langston, A., Pulsipher, et al
AMER SOC CLINICAL ONCOLOGY.2008: 211-17
- **Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL)** *49th Annual Meeting of the American-Society-of-Hematology*

Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Forman, S. J., Agura, E., Chauncey, T., Maziarz, R. T., Maris, M., Shizuru, J., Bruno, B., Wade, J. C., Lange, et al
AMER SOC HEMATOLOGY.2007: 892A-892A